Health Care·Biotechnology·$40.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.21 | N/A | -12.04% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.21 | N/A | -12.04% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a sense of optimism regarding future developments despite the EPS miss. They emphasized their commitment to innovation and growth.
Management expressed confidence in the long-term potential of their pipeline.
They highlighted ongoing efforts to advance their clinical programs.
The earnings report shows that Alnylam Pharmaceuticals did not meet EPS expectations, which typically raises concerns among investors. However, the stock rose by 2.61%, indicating that investors may be optimistic about the company's future prospects and pipeline developments. The lack of revenue data and guidance leaves some uncertainty, but management's positive outlook may have reassured investors.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
NOVO-NORDISK A S ADR
Apr 29, 2016